Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ecancermedicalscience

02:35 EST 11th December 2017 | BioPortfolio

Here are the most relevant search results for "ecancermedicalscience" found in our extensive news archives from over 250 global news sources.

More Information about ecancermedicalscience on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ecancermedicalscience for you to read. Along with our medical data and news we also list ecancermedicalscience Clinical Trials, which are updated daily. BioPortfolio also has a large database of ecancermedicalscience Companies for you to search.

Showing News Articles 1–25 of 1,300+ from ecancermedicalscience

Sunday 10th December 2017

Epidemiology data for acute myeloid leukaemia and the ALESE study

Dr Foran speaks with ecancer at the 2017 ASH annual meeting about the ALESE study of intensive therapy in older adults with newly diagnosed acute myeloid leukaemia. The ALESE study documents the ability to collect epidemiology data within a clinical...

Combination of steroids with ponatinib as frontline therapy for acute lymphoblastic leukaemia

Dr Martinelli spoke to ecancer at the 2017 ASH annual meeting about the first report from the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with philadelphia...

ASPIRE update: Carfilzomib for relapsed / refractory myeloma

Prof Stewart speaks with ecancer at the 2017 ASH annual meeting about updated data from the ASPIRE study looking at the use of carfilzomib in multiple myeloma. Prof Stewart spoke with ecancer about the ASPIRE study at the 2014 ASH annual...

Early platelet drop in myelodysplastic syndrome highlights prognostic classifier

Dr Itzykson speaks with ecancer at the 2017 ASH annual meeting about a prognostic classifier based on early platelet drop in lower-risk myelodysplastic syndrome. He highlights that early drop in platelets during the first 6 months of follow-up holds...

Six-month follow up of CTL019 for diffuse large B-Cell lymphoma

Dr Schuster speaks with ecancer at the ASH 2017 annual meeting about the six-month analysis of the JULIET trial of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma.  Read the news story or watch the press conference for more...

New treatment strategies for multiple myeloma

Dr Kochenderfer speaks with ecancer at the ASH 2017 annual meeting about clinical activity seen with anti-BCMA CAR T-cell therapy in a phase 1 study of people with heavily pre-treated multiple myeloma.  Read the news story or watch the press conference...

Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-Cell lymphoma

Dr Schuster presents, in a press conference at the 2017 ASH annual meeting, data from the phase 2 JULIET trial looking at CTL019 (tisagenlecleucel) in adult patients with relapsed or refractory diffuse large B-Cell lymphoma. Read the news story for...

Anti-bcma CAR T cell therapy for multiple myeloma

Dr Kochenderfer presents, in a press conference at the 2017 ASH annual meeting, updated results from a multicenter study of bb2121 anti-bcma CAR T cell therapy. Read the news story for more.

Axicabtagene ciloleucel for patients with non-hodgkin lymphoma

Dr Neelapu presents, in a press conference at the 2017 ASH annual meeting, data from long term follow up of the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory aggressive non-hodgkin lymphoma. Watch the interview with Dr...

Brentuximab vedotin and the Echelon-1 study

Dr Connors presents, in a press conference at the 2017 ASH annual meeting, data from the phase 3 Echelon-1 study looking at brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine as frontline therapy in patients with previously untreated stage III...

Data from the CLARITY trial of ibrutinib plus venetoclax

Prof Hillmen presents, in a press conference at the 2017 ASH annual meeting, data from the CLARITY trial looking at ibrutinib plus venetoclax in relapsed, refractory CLL. Read the news story for more.

Mogamulizumab for cutaneous T- cell lymphoma

Prof Kim presents, in a press conference at the ASH 2017 annual meeting, data from a randomized trial looking into mogamulizumab, a monoclonal antibody directed against chemokine receptor 4, for patients with cutaneous T- cell lymphoma. Read the news...

Phase 1 study of Blu-285 in advanced systemic mastocytosis

Prof DeAngelo presents, in a press conference at the ASH 2017 annual meeting, data from a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V  in Advanced Systemic Mastocytosis. Read the news story or watch the interview with...

New treatments for acute myeloid leukaemia

Dr Halpern speaks with ecancer at the 2017 ASH annual meeting about the final results from the phase 1/2 trial looking at G-CSF, cladribine, cytarabine, and dose-escalated mitoxantrone (GCLAM) in adults with relapsed/refractory acute myeloid leukaemia or...

ASH 2017: Clinical activity seen with anti-BCMA CAR T-cell therapy in phase 1 study of people with heavily pre-treated multiple myeloma

A one-time infusion of an investigational CAR T-cell therapy that targets a protein found on most multiple myeloma cells elicited an 86-percent overall response rate in 21 patients whose disease had come back or had not responded after a median of seven...

ASH 2017: Six-month analysis of tisagenlecleucel in stubborn form of lymphoma shows sustained responses

Six months after receiving a single dose of tisagenlecleucel, a CAR T-cell therapy that targets CD-19, high response rates persist among adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to researchers. This...

ASH 2017: Responses to CAR T-cell therapy still strong after one year in patients with refractory NHL

Among 108 patients with fast-growing and refractory aggressive non-Hodgkin lymphoma (NHL), more than half were still alive at least a year after receiving a single infusion of a CAR T-cell therapy, axicabtagene ciloleucel (axi-cel), that targets the CD-19...

Echelon-1 study of brentuximab vedotin as frontline therapy

Dr Connors speaks with ecancer at the 2017 ASH annual meeting about the phase 3 Echelon-1 study looking at brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine as frontline therapy in patients with previously untreated stage III or IV hodgkin...

Ibrutinib plus venetoclax in the CLARITY trial

Prof Hillmen speaks with ecancer at the 2017 ASH annual meeting about the CLARITY trial looking at ibrutinib plus venetoclax in relapsed, refractory CLL Read the news story and watch the press conference for more.  ecancer's filming has been kindly...

ASH 2017: Rapid responses, few adverse effects seen with targeted agent in Phase I trial in rare blood disorder

In a Phase I trial, patients with an advanced or aggressive form of systemic mastocytosis (AdvSM), a rare blood disorder, had rapid and durable responses with few adverse effects following treatment with an investigational drug that targets the genetic...

ASH 2017: Combination treatment with two targeted agents shows promise in previously treated CLL

One-third of patients with previously treated chronic lymphocytic leukaemia (CLL) had no detectable disease after six months of combination therapy with the targeted agents ibrutinib and venetoclax, with no increase in the occurrence of tumour lysis...

ASH 2017: Addition of targeted drug reduces risk of first-line treatment failure in advanced Hodgkin lymphoma

Patients with advanced Hodgkin lymphoma (HL) who were treated with a multi-drug regimen that included the targeted agent brentuximab vedotin (BV) had a 23-percent reduction in the risk of disease progression, death, or the need for additional therapy,...

ASH 2017: Targeted antibody mogamulizumab superior to vorinostat for previously treated CTCL in phase III trial

In a large, international, randomised Phase III trial, patients with previously treated cutaneous T-cell lymphoma (CTCL) who received the investigational targeted drug mogamulizumab had significantly better progression-free survival, response rate, and...

Saturday 9th December 2017

For leukaemia patients, transfusion needs may delay hospice care

Toward the end of life, some leukaemia patients depend on blood transfusions to ease their suffering. Unfortunately, the likelihood that transfusions won't be accessible through hospice care appears to be pose a significant barrier to meaningful use of...

Long term follow up on the ZUMA-1 trial

Dr Neelapu speaks with ecancer at the 2017 ASH annual meeting about the long term follow up of the ZUMA-1 trail, looking at axicabtagene ciloleucel in patients with refractory aggressive non-Hodgkin lymphoma. He highlights that axicabtagene ciloleucel...


Quick Search
Advertisement
 

News Quicklinks